4.7 Article

Venous and arterial thrombosis associated with abemaciclib therapy for metastatic breast cancer

期刊

CANCER
卷 128, 期 17, 页码 3224-3232

出版社

WILEY
DOI: 10.1002/cncr.34367

关键词

abemaciclib; arterial thrombosis; breast cancer; CDK 4; 6 inhibitors; venous thromboembolism

类别

资金

  1. American Society of Hematology Scholar Award

向作者/读者索取更多资源

The CDK4/6 inhibitor abemaciclib, a mainstay of treatment for hormone receptor-positive breast cancer, is associated with a higher rate of venous thromboembolism (VTE) in real-world populations compared to clinical trials. Patients who develop thrombosis while on abemaciclib have a significantly higher risk of death.
Background The CDK4/6 inhibitor abemaciclib is a mainstay of treatment for hormone receptor-positive breast cancer. However, increased venous thromboembolism (VTE) rates in multiple clinical trials resulted in a black-box warning for this agent. Thrombosis rates in unselected real-world populations receiving abemaciclib remain ill defined. Methods A multicenter observational cohort study was conducted of patients with metastatic breast cancer receiving abemaciclib. The primary end point was thrombosis during treatment or within 30 days of discontinuation. Multivariable logistic models assessed predictors of VTE, and a multivariable Cox proportional hazards model assessed mortality. Results A total of 364 patients were included, with a median treatment duration of 5.5 months. Twenty-six patients developed 27 (7.4%) thrombotic events (17 VTE, nine arterial thrombosis, and one with both events). No baseline characteristics were associated with increased VTE risk in multivariable modeling. Patients developing VTE during therapy had a higher risk of death than those who did not (hazard ratio, 2.09; 95% CI, 1.07-4.13). Median survival in patients who developed VTE compared with those who did not was 9.6 vs 25.8 months, respectively. The rate of VTE and any thrombosis during abemaciclib therapy was 9.1 and 13.7 events per 100 person-years, respectively, which is notably higher than rates observed in clinical trials. Conclusions In a real-world setting, abemaciclib was associated with a VTE rate approximately two-fold greater than the already elevated rates reported in the MONARCH trials. Patients developing thrombosis on abemaciclib had a significantly higher risk of death. Given these findings, studies evaluating the role of thromboprophylaxis in patients receiving abemaciclib are needed.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据